Also trades as: 0HB0.L (LSE) · $vol 0M
AGIO NASDAQ
Agios Pharmaceuticals, Inc.
1W: -7.7%
1M: +2.1%
3M: +46.0%
YTD: +36.0%
1Y: -6.8%
3Y: +37.8%
5Y: -34.4%
$35.99
-0.98 (-2.65%)
Pre-Market: $36.83 (+0.84, +2.33%)
Weekly Expected Move ±10.8%
$29
$32
$36
$40
$44
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress1 trades
ETF Holdings—
Key Statistics
Market Cap$2.1B
52W Range22.24-46
Volume802,336
Avg Volume1,082,614
Beta0.54
Dividend—
Analyst Ratings
Company Info
CEOBrian Goff
Employees540
SectorHealthcare
IndustryBiotechnology
IPO Date2013-07-24
Websiteagios.com
88 Sidney Street
Cambridge, MA 02139-4169
US
Cambridge, MA 02139-4169
US
617 649 8600
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Latest News
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Neurocrine Gears Up to Report Q2 Earnings: What's in the Cards?
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Backstrom Jay T. | A-Award | 1,447 | — | 2026-07-08 |
| Backstrom Jay T. | M-Exempt | 1,447 | — | 2026-07-08 |
| Gheuens Sarah | M-Exempt | 8,375 | — | 2026-07-01 |
| Gheuens Sarah | S-Sale | 4,007 | $37.56 | 2026-07-01 |
| Gheuens Sarah | M-Exempt | 8,375 | — | 2026-07-01 |